pan-PI3K inhibitor CLR457

An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More